Paul Forman, MD
Family Medicine · Talkeetna, AKNPI 1871606004
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AbbVie at 27.5% of the total.
Across 90 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$507
- GSK$272
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$209
- Pfizer$156
- AstraZeneca$100
- Merck$90
- plus $507 from 15 others
What the payments were for
- Food & beverage$1,841100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 20 | $507 |
| GSK | 13 | $272 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $209 |
| Pfizer | 8 | $156 |
| AstraZeneca | 7 | $100 |
| Merck | 6 | $90 |
| Novo Nordisk | 4 | $79 |
| Eisai Inc. | 3 | $56 |
| Exact Sciences | 3 | $50 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Novartis | 2 | $43 |
| Amgen | 2 | $38 |
| Indivior Inc. | 2 | $36 |
| Amarin Pharma, Inc. | 2 | $35 |
| Boehringer Ingelheim | 1 | $21 |
| Baxter Healthcare | 1 | $19 |
| Acadia Pharmaceuticals Inc | 1 | $19 |
| Alkermes, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,841 in reported general payments places this provider in the 85th percentile of 334 family medicine providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $68,651 |
| EliquisApixaban | 27 | $34,845 |
| OzempicSemaglutide | 19 | $27,341 |
| JanuviaSitagliptin Phosphate | 21 | $25,564 |
| XareltoRivaroxaban | 15 | $23,712 |
| RybelsusSemaglutide | 12 | $22,172 |
| MounjaroTirzepatide | 13 | $21,209 |
| JardianceEmpagliflozin | 12 | $19,459 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $14,184 |
| Xtampza ErOxycodone Myristate | 14 | $4,996 |
| SymbicortBudesonide/Formoterol Fumarate | 12 | $3,618 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $3,045 |
| Ventolin HfaAlbuterol Sulfate | 39 | $2,557 |
| ValacyclovirValacyclovir Hcl | 13 | $1,741 |
| Gabapentin | 50 | $1,719 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $272 | $82,83579 claims |
| Novo NordiskOzempic, Rybelsus | $79 | $49,51331 claims |
| PfizerEliquis | $156 | $34,84527 claims |
| MerckJanuvia | $90 | $25,56421 claims |
| Boehringer IngelheimJardiance | $21 | $19,45912 claims |
| AstraZenecaSymbicort | $100 | $3,61812 claims |
| AbbVieSynthroid | $507 | $1,59413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 334 family medicine providers in Alaska.
Other family medicine in Talkeetna
- Robert SkalaEagle River$38K
- John CullenValdez$32K
- Mary FolandAnchorage$15K
- Ilona FarrAnchorage$14K
- Eric MiknichAnchorage$13K
- Ray KelleyWasilla$9K
- Russell PierceFairbanks$7K
- Heather JonesEagle River$7K
- Frank GreathouseWasilla$7K
- Allison KelliherAnchorage$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.